Reich Kristian's Form 4 filing
MoonLake Immunotherapeutics (MLTX) · filed Dec 10, 2025
- Accession no.
- 0001213900-25-120105
- Filed
- Dec 10, 2025
- Trade date
- Dec 8-9, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market sales total $3.01M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Reich KristianCIK 0001920553 | Officer (Chief Scientific Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 8, 2025 | Class A ordinary shares, par value $0.0001 per share | SSaleDisposed | −130,000 | $15.08F2 | −$1,960,400 | 72,908 | Direct | |
| Dec 9, 2025 | Class A ordinary shares, par value $0.0001 per share | SSaleDisposed | −72,908 | $14.43 | −$1,052,062.44 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $15.036949 to $15.101507. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.